Financial PerformanceThe company delivered a solid set of results, marked by double-digit top-line growth and continued its long-term investment cycle.

International ExpansionInternational operations remain the key growth driver, with PharmaNutra now present in 92 countries.

Market PositionSolid momentum was recorded across the main product families, with Sideral® confirming its market leadership in Italy.

Bears Say

Margin ConstraintsManagement anticipates margin constraints in 2025-26 due to increased investments.

ProfitabilitySignificant investments in new initiatives are expected to lead to a slight reduction in margins over the next two years.

Revenue ProjectionsThe expected tangible results from PHN USA in H2 2025 are below expectations, affecting revenue projections.

PharmaNutra SpA News

PharmaNutra SpA: Strong Growth Potential and Strategic Expansion Drive Buy Rating

Intermonte analyst Giorgio Tavolini maintained a Buy rating on PharmaNutra SpA (PHN – Research Report) yesterday and set...

4M ago

PharmaNutra SpA: Strong International Sales and Financial Health Drive Buy Rating Despite Profitability Concerns

PharmaNutra SpA (PHN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

4M ago

PharmaNutra SpA (PHN) Declares Q2 Dividend: Important Details for Shareholders

PharmaNutra SpA (Milan: PHN) has declared, under its dividend policy, a yearly cash dividend in the amount of...

5M ago

PharmaNutra SpA: Promising Growth Prospects and Strategic Expansion Justify Buy Rating

In a report released yesterday, Daniele Alibrandi from Stifel Nicolaus reiterated a Buy rating on PharmaNutra SpA (PHN...

5M ago

PharmaNutra SpA: Strong Performance and Strategic Growth Drive Buy Rating

In a report released on March 17, Giorgio Tavolini from Intermonte maintained a Buy rating on PharmaNutra SpA...

6M ago

PharmaNutra SpA: Strong Financial Performance and Strategic Growth Justify Buy Rating

In a report released on March 17, Corentin Marty from TP ICAP MIDCAP maintained a Buy rating on...

6M ago

PharmaNutra SpA: Strong Financial Performance and Strategic Expansion Justify Buy Rating

Stifel Nicolaus analyst Daniele Alibrandi reiterated a Buy rating on PharmaNutra SpA (PHN – Research Report) today and...

6M ago

PharmaNutra Expands into Canada with New Deal

PharmaNutra SpA (IT:PHN) has released an update. PharmaNutra S.p.A. has signed a distribution agreement with Sigma Lifesciences to...

9M ago

PharmaNutra Reports Strong Sales Growth in China

PharmaNutra SpA (IT:PHN) has released an update. PharmaNutra S.p.A. has achieved significant sales growth in China for its...

10M ago

PharmaNutra S.p.A. Achieves Strong Revenue Growth

PharmaNutra SpA (IT:PHN) has released an update. PharmaNutra S.p.A. has reported another impressive quarter, showcasing a 17% increase...

10M ago

PHN FAQ

What was PharmaNutra SpA’s price range in the past 12 months?

PharmaNutra SpA lowest stock price was €45.20 and its highest was €61.20 in the past 12 months.

What is PharmaNutra SpA’s market cap?

PharmaNutra SpA’s market cap is €471.95M.

When is PharmaNutra SpA’s upcoming earnings report date?

PharmaNutra SpA’s upcoming earnings report date is Sep 08, 2025 which is in 6 days.

How were PharmaNutra SpA’s earnings last quarter?

PharmaNutra SpA released its earnings results on May 12, 2025. The company reported €0.25 earnings per share for the quarter, beating the consensus estimate of N/A by €0.25.

Is PharmaNutra SpA overvalued?

According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PharmaNutra SpA pay dividends?

PharmaNutra SpA pays a Annually dividend of €1 which represents an annual dividend yield of 2.05%. See more information on PharmaNutra SpA dividends here

What is PharmaNutra SpA’s EPS estimate?

PharmaNutra SpA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PharmaNutra SpA have?

PharmaNutra SpA has 9,680,977 shares outstanding.

What happened to PharmaNutra SpA’s price movement after its last earnings report?

PharmaNutra SpA reported an EPS of €0.25 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.739%.

Which hedge fund is a major shareholder of PharmaNutra SpA?

Currently, no hedge funds are holding shares in IT:PHN

Company Description

PharmaNutra SpA

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.